1417743-41-9 Usage
General Description
The chemical "(1S,3R,5S)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid" is a compound with a complex and specific structure. It is a derivative of the bicyclic compound azabicyclo[3.1.0]hexane, with a tert-butoxycarbonyl group attached. (1S,3R,5S)-2-(tert-butoxycarbonyl)-2-azabicyclo[3.1.0]hexane-3-carboxylic acid is a carboxylic acid, meaning it contains a carboxyl functional group, which gives it acidic properties. The specific arrangement of atoms in this compound makes it valuable for use in chemical reactions, particularly in the field of organic synthesis. The tert-butoxycarbonyl group can also act as a protective group during chemical reactions, allowing for selective manipulation of other functional groups present in a molecule. Therefore, this compound has potential applications in pharmaceutical drug development, as well as in the synthesis of other complex organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 1417743-41-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,1,7,7,4 and 3 respectively; the second part has 2 digits, 4 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1417743-41:
(9*1)+(8*4)+(7*1)+(6*7)+(5*7)+(4*4)+(3*3)+(2*4)+(1*1)=159
159 % 10 = 9
So 1417743-41-9 is a valid CAS Registry Number.
1417743-41-9Relevant articles and documents
CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
-
Page/Page column 54; 55, (2013/03/26)
There is described a novel group of cyclic amine derivative compounds, having an EP4 receptor antagonistic activity and specifically pharmaceutical compounds which are useful for the treatment or alleviation of Prostaglandin E mediated diseases. The present invention therefore relates to novel compounds which are selective antagonists of the EP 4 sub type of PGE2 receptors with analgesic and antinflammatory activity, processes for their preparation, pharmaceutical compositions containing them and theiruse as medicaments, inter alia for the treatment or alleviation of Prostaglandin E mediated diseases such as acute and chronic pain, osteoarthritis, inflammation-associated disorder as arthritis, rheumatoid arthritis, cancer, migraine and endometriosis.
